Showing 5841-5850 of 8816 results for "".
- North America's Scar Treatment Poised for Growth Spurt by 2022https://practicaldermatology.com/news/north-america-scar-treatment-market-set-to-grow-by-2022/2458629/Scar treatment will be a hot growth area in coming years, according to a new report by Persistence Market Research. The report cites a rising incidence of burn and trauma cases and an increasing preval
- Vitals Report: National Average Wait Time Down Nearly 10% since 2009https://practicaldermatology.com/news/vitals-report-national-average-wait-time-down-nearly-10-since-2009/2458630/When it comes to waiting for a doctor’s appointment, most patients are waiting 19 minutes, 19 seconds, according to Vitals 7th annual wait time report This is down nearly 10 percent from the average 21 minutes and 18 seconds patients once sp
- Take That, Melanoma! New Patch Delivers Anti-PD-1 Antibodies Directly to Skin Cancerhttps://practicaldermatology.com/news/take-that-melanoma-new-patch-delivers-anti-pd-1-antibodies-directly-to-skin-cancer/2458633/A new patch embedded with microneedles may deliver anti-PD-1 antibodies directly to the site of melanoma, according to a study in Nano Letters. In animal studies, the technique more effectively targeted
- Valeant Announces CEO Succession Plan And Changes To Board; Provides Accounting And Financial Reporting Updatehttps://practicaldermatology.com/news/valeant-announces-ceo-succession-plan-and-changes-to-board-provides-accounting-and-financial-reporting-update/2458640/Valeant’s board has initiated a search to identify a candidate to succeed J. Michael Pearson as chief executive officer (CEO). Mr. Pearson will continue to serve as CEO and a director until his replacement is appointed. The company also announced that William A. Ackman, CEO of Persh
- Many Parents are Concerned About Fake Online MD Reviewshttps://practicaldermatology.com/news/many-parents-are-concerned-about-fake-online-md-reviews/2458637/More than two-thirds of parents believe some online doctor reviews are fake, while slightly fewer say there are not enough ratings to make a good decision, according a report from C.S. Mott Children’s Hospital National Poll on Children’s Health. More than half of p
- Vitae Achieves Proof-of-Concept with First-in-Class RORyt Inhibitor for Psoriasishttps://practicaldermatology.com/news/vitae-achieves-proof-of-concept-with-first-in-class-roryt-inhibitor-for-psoriasis/2458643/Vitae Pharmaceuticals, Inc. shared positive top-line results from its Phase 2a proof-of-concept clinical trial of VTP-43742 in psoriatic patients. VTP-43742 is Vitae's wholly owned, first-in-class, orally active RORγt inhibitor with the potential to transform the treatment of multiple a
- Bernie Sanders Urges Treasury to Block Pfizer-AGN Mergerhttps://practicaldermatology.com/news/bernie-sanders-urges-treasury-to-block-pfizer-agn-merger/2458642/Democratic presidential hopeful Bernie Sanders is urging the US Treasury to prevent the Pfizer-Allergan deal, according to media reports. Calling it a ‘tax scam” in a
- FDA Approves PMA Supplement for MelaFind from STRATA Scienceshttps://practicaldermatology.com/news/fda-accepts-pma-for-melafind-from-strata-sciences/2458644/The FDA has approved STRATA Skin Sciences, Inc.’s PMA supplement for the MelaFind System. The FDA approved MelaFind’s use of the “classifier score data”, a quantitative result derived by the MelaFind System that can be beneficially used in conjunction with the previously a
- New Research Suggests Why PD-1 Blockers Don't Work for All Melanoma Patientshttps://practicaldermatology.com/news/new-research-suggests-why-pd-1-blockers-dont-work-for-all-melanoma-patients/2458645/Immunotherapy using anti-PD-1 antibodies has been a game change for metastatic melanoma patients, but 60 to 70 percent of patients’ melanoma tumors are resistant to the anti-PD-1 antibodies. Now new research out of UCLA suggests that patterns of gene
- Revance Therapeutics Appoints Roman G. Rubio, MD, MBA, as Senior Vice President of Clinical Developmenthttps://practicaldermatology.com/news/revance-therapeutics-appoints-roman-g-rubio-md-mba-as-senior-vice-president-of-clinical-development/2458649/Revance Therapeutics, Inc. has named Roman G. Rubio, MD, MBA Senior Vice President of Clinical Development. Dr. Rubio will report to Chief Operating Officer Abhay Joshi, and will lead the company’s clinical development team, focusing on further accelerating the advancement of Reva